CoChat

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Open access
Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, Windsor, Kevin · 2022 · The Lancet Haematology

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

BACKGROUND Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. We aimed to assess these regimens in patients with newly diagnosed multiple myeloma who are ineligible for haematopoietic stem-cell transplantation (HSCT). METHODS ELOQUENT-1 is an open-label, multicentre, randomised, phase 3 trial conducted at 185 hospitals, oncology practices, and research centres in 19 countries. Eligible patients were aged 18 years or older with newly diagnosed, untreated, symptomatic myeloma and not candidates for high-dose therapy plus HSCT, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower. Patients were randomly assigned (1:1) to receive elotuzumab plus lenalidomide and dexamethasone or lenalidomide and dexamethasone using an interactive voice response system, stratified by the International Staging System (ISS; stage I-II vs III), age (<75 years vs ≥75 years), and ECOG performance status (0 vs 1-2). Patients in the elotuzumab plus lenalidomide and dexamethasone group received elotuzumab administered intravenously at 10 mg/kg on days 1, 8, 15, and 22 during cycles 1 and 2, days 1 and 15 during cycles 3-18, and then at 20 mg/kg on day 1 for subsequent cycles. In both treatment groups, patients received 25 mg lenalidomide orally on days 1-21 of each cycle and 40 mg dexamethasone on days 1, 8, 15, and 22 of each cyc…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(22)00103-x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 29 references

Cited by

See all 54

Metadata

Authors
Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M.-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y.-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K., Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M.-V., Špička, I., Lazaroiu, M., Berdeja, J., Kaufman, J. L., Jou, Y.-M., Ganetsky, A., Popa McKiver, M., Lonial, S., Weisel, K., Sandhu, I., Podhorecka, M., Palumbo, A., Shacham-Abulafia, A., Vaxman, I., Shpilberg, O., Besemer, B., Martelli, M., Foà, R., De Fabritiis, P., Caravita di Toritto, T., Gheorghita, E., Oriol, A., Rowlings, P., Emanuele, A., Carella, A. M., Offidani, M., Bladé, J., Casado, L. F., Oakervee, H., Panelli, V., Meza, L., Kühr, T., Granell, M., Benson, D., Nair, R., Holden, V., Reeves, J., Eek, R. W., Walker, P. A., Catalano, J., Rosta, A., Lech-Marańda, E., Samaras, C., Reiman, A., Weaver, R., Acs, P., Grigg, A., De Prijck, B., Louzada, M., Minuk, L., Sebag, M., Klausmann, M., Welslau, M., Hellmann, A., Danaila, C., Becker, P., Bensinger, W., Porterfield, B., Modiano, M., Schultz, S. M., Manges, R., Lee, H.-S. C., Gray, J. X., Wright, M. P., Vekemans, M.-C., Hamed, A., Gasztonyi, Z., Mikala, G., Masszi, T., Gamberi, B., Kuliczkowski, K., Usnarska-Zubkiewicz, L., Bengoechea, E., Gutiérrez, M. A., García, M. T., San-Miguel, J., Driessen, C., Behl, R., Brenner, W., Gray, C., Hansen, V., Moezi, M., Cortes, H. V., Yen, C., Gressot, L., Horvath, N., D'Rozario, J. M., Latimer, M., Kyrtsonis, M.-C., Chubar, E., Mittelman, M., Baldini, L., Tosi, P., Vacca, A., Jędrzejczak, W. W., Robak, T., Lahuerta, J. J., Carney, J., Chen, F., Hirsch, R., Ruiz, M., Alencar, A., Jagasia, M., Kasbari, S., Kuriakose, P., Mahmood, A., Chaudhry, M., Cohen, G., Noga, S., Roa, S., Jakubowiak, A., Rosenbaum, C., Delforge, M., Delrieu, V., Doyen, C., Dries, D., Demuynck, H., Schots, R., Maisnar, V., Blau, I. W., Dürk, H. A., Kerkhoff, A., Kropff, M., Munder, M., Röllig, C., Scheid, C., Symeonidis, A. S., Illés, Á., Coyne, M., O'Gorman, P., Hayden, P., O'Dwyer, M., Ben-Yehuda, D., Braester, A., Nemets, A., Lugassy, G., Cohen, Y., Rahimi-Levene, N., Bosi, A., Pezzatti, S., Rossini, F., Pogliani, E. M., Pinto, A., Komarnicki, M., Borsaru, G., Stoia, R., Afanasyev, B., Goñi, M. A., Carboneras, A. V., Ali, S., Rubenstein, S. E., Caputto, S., Cosgriff, T., Fanning, S., Khojasteh, A., Liman, A., Malcolm, A., Vrindavanam, N., Patel, R., Belani, R., Shieh, M., Stockerl-Goldstein, K., Strnad, C., Stuart, R., Chhabra, S., Costa, L., Jhangiani, H., Augustson, B., Filshie, R., Johnston, A., Hertzberg, M. S., Mineur, P., Fox, S., Kotb, R., Dao, V., LeBlanc, R., Gregora, E., Brioli, A., Mügge, L.-O., Hänel, M., Langer, C., Kapsali, E., Briasoulis, E., Kyriakou, D., Hardan, I., Horowitz, N. A., Clotilde, C., Fabbiano, F., Castagnari, B., Ciceri, F., Musuraca, G., Deptała, A., Kłoczko, J., Balea, M., Vladareanu, A.-M., Rossiev, V., Alegre, A., Encinas, C., Gayoso, J., Pabst, T., Rabin, N., Arledge, S., Cabanillas, F., Catlett, J., Chidiac, T., Clarkson, D., Dhodapkar, M., Geils, G., Khan, C. M., Sahovic, E., Khasawneh, M., Sehgal, R., Ballester, O., Levy, M., Fay, J., Liem, K., Lunning, M., Vose, J., Faber, E., MacFarlane, D., Hohl, R., Mahmood, T., Bhaskar, B., Mims, M., Oliff, I., Paner, A., Maciejewski, J., Padmanabhan, A., Richard, R., Sanyal, A., Schiller, G., Staszewski, H., Stevens, D., Vaughn, C., & Windsor, K.
Affiliations
  • Instituto de Investigación Biomédica de Salamanca (ES)
  • Princess Margaret Cancer Centre (CA)
  • University of Alberta (CA)
  • Heidelberg University (DE)
  • Istituto di Ematologia di Bologna (IT)
  • Dana-Farber Cancer Institute (US)
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2022-06
Volume
9
Issue
6
Pages
e403-e414
ISSN
2352-3026 (ISSN-L)
OpenAlex
W4229458082
Cited by
48
References
29
Citations by year
2026: 5 · 2025: 8 · 2024: 15 · 2023: 12 · 2022: 8
FWCI
7.82
Type
journal article
Language
en
Open access
Locations
  • The Lancet Haematology (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
  • Open Access CRIS of the University of Bern
Funders
  • Bristol-Myers Squibb Co Summit
  • Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
elotuzumab, lenalidomide, dexamethasone, newly diagnosed multiple myeloma, progression-free survival, overall survival, CD117, CXCR4, myeloma treatment, International Staging System, ECOG performance status
MeSH terms
Lenalidomide, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Male, Multiple Myeloma, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2352-3026(22)00103-x
The paper
Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., Magen, H., Larocca, A., Laubach, J. P., Petrucci, M. T., Reece, D., White, D., Mateos, M.-V., Špička, I., Lazaroiu, M., . . . Windsor, K. (2022). Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(22)00103-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.